CBD trial targets Alzheimer's risk: can it slow memory decline?

NCT ID NCT05822362

Recruiting now Disease control Sponsor: University of Colorado, Denver Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tests whether cannabidiol (CBD) can slow the progression of Alzheimer's disease in people aged 55-85 with mild cognitive impairment (early memory loss). Over 236 participants will receive either CBD or a placebo for a period, and researchers will measure changes in memory, thinking skills, and blood markers linked to Alzheimer's. The goal is to see if CBD can help control the disease and delay further decline.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for MILD COGNITIVE IMPAIRMENT are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

Alzheimer disease cannabis dependence Cognitive Dysfunction

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

MILD COGNITIVE IMPAIRMENT

Contacts and locations

Show contact details

Study contacts

Contact

Phone: •••-•••-•••• Email: •••••@•••••

Locations

University of Colorado - Anschutz Medical Campus
RECRUITING

Aurora, Colorado, 80045, United States

Contact Email: •••••@•••••

Contact Email: •••••@•••••